Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CAR-T Bridging HSCT in B-cell Malignancies
NCT02846584Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Jul 2016
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 CAR-T cells and anti-CD20 CAR-T cells (Southwest Hospital) in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and B-cell malignancy, sponsored by Southwest Health System. Primary endpoint: Overall Survival Rate at 2 years. Status: unknown.
02
Drugs
anti-CD19 CAR-T cellsanti-CD20 CAR-T cells (Southwest Hospital)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)B-cell malignancy
Beyond the preview
Go deeper on NCT02846584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846584.